PET imaging of inflammation in atherosclerosis

Nature Reviews Cardiology

Volumn 11, Issue 8, 2014, Pages 443-457

  Tarkin, Jason M ^a   Joshi, Francis R ^a   Rudd, James H F ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; TRACER;

ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY; CORONARY ARTERY CALCIFICATION; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; HYPOXIA; INFLAMMATION; MACROPHAGE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; MACROPHAGES; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84904730036     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.80     Document Type: Review

References (182)

1. Nichols, M. et al. European Cardiovascular Disease Statistics 2012 Edition (European Heart Network and European Society of Cardiology, 2012).
2. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
3. Go, A. S. et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129, e28-e292 (2014).
4. Motoyama, S. et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J. Am. Coll. Cardiol. 54, 49-57 (2009).
5. Cai, J. et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque. Circulation 112, 3437-3444 (2005).
6. Obaid, D. R. et al. Atherosclerotic plaque composition and classification identified by coronary computed tomography: assessment of computed tomography-generated plaque maps compared with virtual histology intravascular ultrasound and histology. Circ. Cardiovasc. Imaging 6, 655-664 (2013).
7. Osborn, E. A. & Jaffer, F. A. The advancing clinical impact of molecular imaging in CVD. JACC Cardiovasc. Imaging 6, 1327-1341 (2013).
8. Leuschner, F. & Nahrendorf, M. Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic. Circ. Res. 108, 593-606 (2011).
9. Vancraeynest, D., Pasquet, A., Roelants, V., Gerber, B. L. & Vanoverschelde, J. L. Imaging the vulnerable plaque. J. Am. Coll. Cardiol. 57, 1961-1979 (2011).
10. Quillard, T. & Libby, P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ. Res. 111, 231-244 (2012).
11. Wildgruber, M., Swirski, F. K. & Zernecke, A. Molecular imaging of inflammation in atherosclerosis. Theranostics 3, 865-884 (2013).
12. Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32, 2045-2051 (2012).
13. Vita, J. A. Endothelial function. Circulation 124, e906-e912 (2011).
14. De Caterina, R. et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96, 60-68 (1995).
15. Topper, J. N., Cai, J., Falb, D. & Gimbrone, M. A. Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl Acad. Sci. USA 93, 10417-10422 (1996).
16. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894-897 (1998).
17. Falk, E. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 47, C7-C12 (2006).
18. Dutta, P. et al. Myocardial infarction accelerates atherosclerosis. Nature 487, 325-329 (2012).
19. Clinton, S. K. et al. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am. J. Pathol. 140, 301-316 (1992).
20. Ross, R. & Glomset, J. A. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180, 1332-1339 (1973).
21. Stary, H. C. Composition and classification of human atherosclerotic lesions. Virchows Arch. A Pathol. Anat. Histopathol. 421, 277-290 (1992).
22. Libby, P. & Clinton, S. K. Cytokines as mediators of vascular pathology. Nouv. Rev. Fr. Hematol. 34 (Suppl.), S47-S53 (1992).
23. Wexler, L. et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 94, 1175-1192 (1996).
24. Fox, K. et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 27, 1341-1381 (2006).
25. Falk, E., Shah, P. K. & Fuster, V. Coronary plaque disruption. Circulation 92, 657-671 (1995).
26. Kaski, J. C., Chester, M. R., Chen, L. & Katritsis, D. Rapid angiographic progression of coronary artery disease in patients with angina pectoris. The role of complex stenosis morphology. Circulation 92, 2058-2065 (1995).
27. Libby, P. Molecular bases of the acute coronary syndromes. Circulation 91, 2844-2850 (1995).
28. Kolodgie, F. D. et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr. Opin. Cardiol. 16, 285-292 (2001).
29. Galis, Z. S., Sukhova, G. K., Lark, M. W. & Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493-2503 (1994).
30. rd, Lainey, L. L. & Silverman, K. J. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N. Engl. J. Med. 310, 175-177 (1984).
31. Björnheden, T., Levin, M., Evaldsson, M. & Wiklund, O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler. Thromb. Vasc. Biol. 19, 870-876 (1999).
32. Virmani, R. et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler. Thromb. Vasc. Biol. 25, 2054-2061 (2005).
33. Hackett, D. D., Davies, G. G. & Maseri, A. A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur. Heart J. 9, 1317-1323 (1988).
34. Ambrose, J. A. et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J. Am. Coll. Cardiol. 12, 56-62 (1988).
35. Little, W. C. et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 78, 1157-1166 (1988).
36. Davies, M. J. & Thomas, A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N. Engl. J. Med. 310, 1137-1140 (1984).
37. Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A. & Schwartz, S. M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20, 1262-1275 (2000).
38. Virmani, R., Burke, A. P., Farb, A. & Kolodgie, F. D. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 47, C13-C18 (2006).
39. Narula, J. et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J. Am. Coll. Cardiol. 61, 1041-1051 (2013).
40. Stone, G. W. et al. A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364, 226-235 (2011).
41. Calvert, P. A. et al. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc. Imaging 4, 894-901 (2011).
42. Varnava, A. M., Mills, P. G. & Davies, M. J. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 105, 939-943 (2002).
43. Smits, P. C. et al. Coronary artery disease: arterial remodelling and clinical presentation. Heart 82, 461-464 (1999).
44. Mintz, G. S. et al. Atherosclerosis in angiographically 'normal' coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J. Am. Coll. Cardiol. 25, 1479-1485 (1995).
45. Moreno, P. R. et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90, 775-778 (1994).
46. Woollard, K. J. & Geissmann, F. Monocytes in atherosclerosis: subsets and functions. Nat. Rev. Cardiol. 7, 77-86 (2010).
47. Calder, P. C., Dimitriadis, G. & Newsholme, P. Glucose metabolism in lymphoid and inflammatory cells and tissues. Curr. Opin. Clin. Nutr. Metab. Care 10, 531-540 (2007).
48. Martinez, F. O., Sica, A., Mantovani, A. & Locati, M. Macrophage activation and polarization. Front. Biosci. 13, 453-461 (2008).
49. Mantovani, A., Garlanda, C. & Locati, M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler. Thromb. Vasc. Biol. 29, 1419-1423 (2009).
50. Finn, A. V. et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J. Am. Coll. Cardiol. 59, 166-177 (2012).
51. Ghattas, A., Griffiths, H. R., Devitt, A., Lip, G. Y. & Shantsila, E. Monocytes in coronary artery disease and atherosclerosis: where are we now? J. Am. Coll. Cardiol. 62, 1541-1551 (2013).
52. Gupta, S. et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99, 2752-2761 (1997).
53. Pinderski, L. J. et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 90, 1064-1071 (2002).
54. Butcher, M. J. & Galkina, E. V. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front. Physiol. 3, 44 (2012).
55. Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723-737 (2011).
56. Pello, O. M., Silvestre, C., De Pizzol, M. & Andrés, V. A glimpse on the phenomenon of macrophage polarization during atherosclerosis. Immunobiology 216, 1172-1176 (2011).
57. Wilcox, J. N., Smith, K. M., Schwartz, S. M. & Gordon, D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl Acad. Sci. USA 86, 2839-2843 (1989).
58. Mach, F., Schönbeck, U., Bonnefoy, J. Y., Pober, J. S. & Libby, P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96, 396-399 (1997).
59. Izquierdo-Garcia, D. et al. Comparison of methods for magnetic resonance-guided [18-F]fluorodeoxyglucose positron emission tomography in human carotid arteries: reproducibility, partial volume correction, and correlation between methods. Stroke 40, 86-93 (2009).
60. Burg, S. et al. Partial volume effect estimation and correction in the aortic vascular wall in PET imaging. Phys. Med. Biol. 58, 7527-7542 (2013).
61. Büther, F. et al. List mode-driven cardiac and respiratory gating in PET. J. Nucl. Med. 50, 674-681 (2009).
62. Fayad, H. J., Lamare, F., Le Rest, C. C., Bettinardi, V. & Visvikis, D. Generation of 4-dimensional CT images based on 4-dimensional PET-derived motion fields. J. Nucl. Med. 54, 631-638 (2013).
63. Mochizuki, T. et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J. Nucl. Med. 42, 1551-1555 (2001).
64. Alavi, A. & Reivich, M. Guest editorial: the conception of FDG-PET imaging. Semin. Nucl. Med. 32, 2-5 (2002).
65. 18F]-fluorodeoxyglucose positron emission tomography. Circulation 105, 2708-2711 (2002).
66. 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur. J. Nucl. Med. Mol. Imaging 41, 369-383 (2013).
67. 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol. 48, 1818-1824 (2006).
68. 18FDG uptake in atherosclerotic carotid plaques. Nucl. Med. Commun. 31, 423-429 (2010).
69. Græbe, M. et al. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur. J. Vasc. Endovasc. Surg. 37, 714-721 (2009).
70. Rosenbaum, D., Millon, A. & Fayad, Z. A. Molecular imaging in atherosclerosis: FDG PET. Curr. Atheroscler. Rep. 14, 429-437 (2012).
71. 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J. Am. Coll. Cardiol. 58, 603-614 (2011).
72. Camici, P. G., Rimoldi, O. E., Gaemperli, O. & Libby, P. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur. Heart J. 33, 1309-1317 (2012).
73. 18F-FDG uptake in human atherosclerotic carotid plaques. Mol. Imaging Biol. 14, 384-392 (2011).
74. Sluimer, J. C. et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J. Am. Coll. Cardiol. 51, 1258-1265 (2008).
75. Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 364, 656-665 (2011).
76. Boström, P. et al. Hypoxia converts human macrophages into triglyceride-loaded foam cells. Arterioscler. Thromb. Vasc. Biol. 26, 1871-1876 (2006).
77. 18F-FDG imaging of human atherosclerotic carotid plaques reflects gene expression of the key hypoxia marker HIF-1α. Am. J. Nucl. Med. Mol. Imaging 3, 384-392 (2013).
78. 18F-FDG uptake to macrophages in vitro. J. Nucl. Med. 53, 55-58 (2012).
79. Satomi, T. et al. Comparison of contrast agents for atherosclerosis imaging using cultured macrophages: FDG versus ultrasmall superparamagnetic iron oxide. J. Nucl. Med. 54, 999-1004 (2013).
80. Mahabadi, A. A. et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur. Heart J. 30, 850-856 (2009).
81. Hoeksema, M. A., Stöger, J. L. & de Winther, M. P. Molecular pathways regulating macrophage polarization: implications for atherosclerosis. Curr. Atheroscler. Rep. 14, 254-263 (2012).
82. Stöger, J. L., Goossens, P. & de Winther, M. P. J. Macrophage heterogeneity: relevance and functional implications in atherosclerosis. Curr. Vasc. Pharmacol. 8, 233-248 (2010).
83. 18F-FDG PET imaging of atherosclerosis. J. Nucl. Med. 54, 1661-1667 (2013).
84. rd annual meeting of the Society of Nuclear Medicine. Denver, Colorado, June 3-5, 1996. J. Nucl. Med. 37 (5 Suppl.), 1P-346P (1996).
85. nd Scientific Sessions of the American Heart Association. Atlanta, Georgia, USA. November 7-10, 1999. Circulation 100 (18 Suppl.), I1-I928 (1999).
86. Lederman, R. J. et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl. Med. Commun. 22, 747-753 (2001).
87. Yun, M. et al. F-18 FDG uptake in the large arteries: a new observation. Clin. Nucl. Med. 26, 314-319 (2001).
88. 18F-FDG PET scanning exploring plaque vulnerability. J. Nucl. Cardiol. 18, 1066-1075 (2011).
89. Rudd, J. H. et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J. Am. Coll. Cardiol. 50, 892-896 (2007).
90. 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J. Nucl. Med. 49, 871-878 (2008).
91. 18F-FDG uptake with vascular calcification. J. Nucl. Med. 46, 1278-1284 (2005).
92. 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J. Nucl. Med. 50, 563-568 (2009).
93. Nawaz, A. et al. Relation between popliteal-tibial artery atherosclerosis and global glycolytic metabolism in the affected diabetic foot: a pilot study using quantitative FDG-PET. J. Am. Podiatr. Med. Assoc. 102, 240-246 (2012).
94. Rudd, J. H. et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ. Cardiovasc. Imaging 2, 107-115 (2009).
95. 18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J. Am. Coll. Cardiol. 49, 1533-1539 (2007).
96. 18F-FDG-PET/ CT in 141 patients. Mol. Imaging Biol. 11, 455-459 (2009).
97. 18F-fluorodeoxyglucose positron emission tomography. Circ. Cardiovasc. Imaging 3, 142-148 (2010).
98. 18F-FDG uptake to C-reactive protein and Framingham risk score in a large cohort of asymptomatic adults. J. Nucl. Med. 54, 2070-2076 (2013).
99. Bural, G. G. et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur. J. Nucl. Med. Mol. Imaging 35, 562-569 (2008).
100. 18F-FDG PET. J. Nucl. Med. 52, 10-17 (2011).
101. 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J. Nucl. Med. 48, 227-233 (2007).
102. 18F-fluorodeoxyglucose positron emission tomography. Arterioscler. Thromb. Vasc. Biol. 31, 944-949 (2011).
103. 18FDG PET and ultrasound echolucency in carotid artery plaques. JACC Cardiovasc. Imaging 3, 289-295 (2010).
104. Silvera, S. S. et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis 207, 139-143 (2009).
105. Figueroa, A. L. et al. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ. Cardiovasc. Imaging 5, 69-77 (2012).
106. Joly, L. et al. Aortic inflammation, as assessed by hybrid FDG-PET/CT imaging, is associated with enhanced aortic stiffness in addition to concurrent calcification. Eur. J. Nucl. Med. Mol. Imaging 36, 979-985 (2009).
107. Rudd, J. H. et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ. Cardiovasc. Imaging 2, 107-115 (2009).
108. 18F-FDG PET/CT angiography of carotid plaque with immunohistochemical validation. J. Nucl. Med. 52, 1698-1703 (2011).
109. 18F-FDG PET/CT. J. Nucl. Med. 45, 1816-1821 (2004).
110. 18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see. J. Nucl. Cardiol. 19, 1211-1225 (2012).
111. Bucerius, J. et al. Arterial and fat tissue inflammation are highly correlated: a prospective (18)F-FDG PET/CT study. Eur. J. Nucl. Med. Mol. Imaging 41, 934-945 (2014).
112. Grundy, S. M. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 105, 2696-2698 (2002).
113. Apovian, C. M. et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler. Thromb. Vasc. Biol. 28, 1654-1659 (2008).
114. Rosito, G. A. et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 117, 605-613 (2008).
115. Gorter, P. M. et al. Relation of epicardial and pericoronary fat to coronary atherosclerosis and coronary artery calcium in patients undergoing coronary angiography. Am. J. Cardiol. 102, 380-385 (2008).
116. 18F-FDG PET imaging. Circ. Cardiovasc. Imaging http://dx.doi.org/10.1161/CIRCIMAGING.113.001093.
117. 18F-fluorodeoxyglucose- positron emission tomography. Pilot study. Clin. Neurol. Neurosurg. 109, 409-412 (2007).
118. 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 36, 2642-2647 (2005).
119. Moustafa, R. R. et al. Carotid plaque inflammation is associated with cerebral microembolism in patients with recent transient ischemic attack or stroke: a pilot study. Circ. Cardiovasc. Imaging 3, 536-541 (2010).
120. 18F- fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann. Neurol. 71, 709-718 (2012).
121. Paulmier, B. et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J. Nucl. Cardiol. 15, 209-217 (2008).
122. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J. Nucl. Med. 50, 1611-1620 (2009).
123. Grandpierre, S. et al. Arterial foci of F-18 fluorodeoxyglucose are associated with an enhanced risk of subsequent ischemic stroke in cancer patients: a case-control pilot study. Clin. Nucl. Med. 36, 85-90 (2011).
124. Figueroa, A. L. et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc. Imaging 6, 1250-1259 (2013).
125. 18F-FDG uptake and calcification in health-screening subjects. Ann. Nucl. Med. 27, 239-246 (2012).
126. Muntendam, P., McCall, C., Sanz, J., Falk, E. & Fuster, V. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease-study design and objectives. Am. Heart J. 160, 49-57.e1 (2010).
127. Fernández-Ortiz, A. et al. The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design. Am. Heart J. 166, 990-998 (2013).
128. 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J. Nucl. Med. 49, 1277-1282 (2008).
129. Tahara, N. et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol. 48, 1825-1831 (2006).
130. Rudd, J. H., Machac, J. & Fayad, Z. A. Simvastatin and plaque inflammation. J. Am. Coll. Cardiol. 49, 1991 (2007).
131. Ishii, H. et al. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clin. Ther. 32, 2337-2347 (2010).
132. Wu, Y.-W. et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur. J. Nucl. Med. Mol. Imaging 39, 399-407 (2011).
133. Tawakol, A. et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J. Am. Coll. Cardiol. 62, 909-917 (2013).
134. Subramanian, S. et al. High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins. J. Am. Coll. Cardiol. 62, 2382-2391 (2013).
135. Potter, K. et al. Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial. Cerebrovasc. Dis. 27, 259-265 (2009).
136. Elkhawad, M. et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc. Imaging 5, 911-922 (2012).
137. 2 inhibitor, on arterial inflammation as assessed with (18)f-fluorodeoxyglucose-positron emission tomography imaging. J. Am. Coll. Cardiol. 63, 86-88 (2014).
138. 2 inhibition: results from an in vitro study and two randomized phase I trials. PLoS ONE 27, e83094 (2014).
139. Mäki-Petäjä, K. M. et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 126, 2473-2480 (2012).
140. Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597-605 (2011).
141. Everett, B. M. et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am. Heart J. 166, 199-207.e15 (2013).
142. Fayad, Z. A. et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378, 1547-1559 (2011).
143. Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099 (2012).
144. Font, M. A. et al. Imaging of early inflammation in low-to-moderate carotid stenosis by 18-FDG-PET. Front. Biosci. (Landmark Ed.) 14, 3352-3360 (2009).
145. Wassélius, J., Larsson, S. & Jacobsson, H. Time-to-time correlation of high-risk atherosclerotic lesions identified with [(18)F]-FDG-PET/CT. Ann. Nucl. Med. 23, 59-64 (2009).
146. Ben-Haim, S., Kupzov, E., Tamir, A., Frenkel, A. & Israel, O. Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/CT studies. J. Nucl. Cardiol. 13, 791-800 (2006).
147. Saam, T. et al. Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: a PET/CT study. Eur. J. Nucl. Med. Mol. Imaging 37, 1203-1212 (2010).
148. 18F-fluorodeoxyglucose in association with calcification and coronary artery disease: a preliminary study. Nucl. Med. Commun. 30, 287-291 (2009).
149. Rogers, I. S. et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc. Imaging 3, 388-397 (2010).
150. 18F-FDG uptake by fusion of PET and coronary CT angiography at sites of percutaneous stenting for acute myocardial infarction and stable coronary artery disease. J. Nucl. Med. 53, 575-583 (2012).
151. Joshi, N. V. et al. (18)F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 383, 705-713 (2014).
152. 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res. 4, 1 (2014).
153. Rogers, I. S. & Tawakol, A. Imaging of coronary inflammation with FDG-PET: feasibility and clinical hurdles. Curr. Cardiol. Rep. 13, 138-144 (2011).
154. Rudd, J. H. et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J. Am. Coll. Cardiol. 55, 2527-2535 (2010).
155. Patel, Y. C. Somatostatin and its receptor family. Front. Neuroendocrinol. 20, 157-198 (1999).
156. Boy, C. et al. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur. J. Nucl. Med. Mol. Imaging 38, 1224-1236 (2011).
157. Armani, C., Catalani, E., Balbarini, A., Bagnoli, P. & Cervia, D. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J. Leukoc. Biol. 81, 845-855 (2006).
158. Adams, R. L., Adams, I. P., Lindow, S. W., Zhong, W. & Atkin, S. L. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br. J. Cancer 92, 1493-1498 (2005).
159. Dalm, V. A. et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am. J. Physiol. Endocrinol. Metab. 285, E344-E353 (2003).
160. Rominger, A. et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J. Nucl. Med. 51, 193-197 (2010).
161. 18F-FDG, calcium burden and risk factors. EJNMMI Res. 2, 52 (2012).
162. Li, X. et al. Specific somatostatin receptor II expression in arterial plaque: (68)Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. Atherosclerosis 230, 33-39 (2013).
163. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT02021188 (2013).
164. Laitinen, I. et al. Uptake of inflammatory cell marker [11C]PK11195 into mouse atherosclerotic plaques. Eur. J. Nucl. Med. Mol. Imaging 36, 73-80 (2009).
165. Fujimura, Y. et al. Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: an autoradiographic study with [(3)H]PK 11195. Atherosclerosis 201, 108-111 (2008).
166. Bird, J. L. et al. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis. Atherosclerosis 210, 388-391 (2010).
167. Pugliese, F. et al. Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography. J. Am. Coll. Cardiol. 56, 653-661 (2010).
168. Gaemperli, O. et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur. Heart J. 33, 1902-1910 (2012).
169. Shalhoub, J., Oskrochi, Y., Davies, A. H. & Owen, D. R. Clinical assessment of carotid atherosclerosis inflammation by positron emission tomography. Curr. Mol. Med. 13, 1646-1652 (2013).
170. Owen, D. R., Lindsay, A. C., Choudhury, R. P. & Fayad, Z. A. Imaging of atherosclerosis. Annu. Rev. Med. 62, 25-40 (2011).
171. Laitinen, I. E. et al. Uptake of 11C-choline in mouse atherosclerotic plaques. J. Nucl. Med. 51, 798-802 (2010).
172. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler. Thromb. Vasc. Biol. 26, 584-589 (2005).
173. 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans-first results. Eur. J. Nucl. Med. Mol. Imaging 35, 815-820 (2008).
174. Kato, K. et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur. J. Nucl. Med. Mol. Imaging 36, 1622-1628 (2009).
175. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01899014 (2013).
176. Marsch, E., Sluimer, J. C. & Daemen, M. J. Hypoxia in atherosclerosis and inflammation. Curr. Opin. Lipidol. 24, 393-400 (2013).
177. 18F-fluoromisonidazole PET imaging. Circ. Cardiovasc. Imaging 7, 312-320 (2014).
178. 18F- fluorodeoxyglucose positron emission tomography (abstract 14673). Circulation 128 (22 Suppl.) A14673 (2013).
179. Paeng, J. C. et al. Feasibility and kinetic characteristics of (68)Ga-NOTA-RGD PET for in vivo atherosclerosis imaging. Ann. Nucl. Med. 27, 847-854 (2013).
180. Beer, A. J. et al. PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis. JACC Cardiovasc. Imaging 7, 178-187 (2014).
181. Kataoka, Y. et al. Spotty calcification as a marker of accelerated progression of coronary atherosclerosis: insights from serial intravascular ultrasound. J. Am. Coll. Cardiol. 59, 1592-1597 (2012).
182. Vengrenyuk, Y. et al. A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc. Natl Acad. Sci. USA 103, 14678-14683 (2006).